You are here

Idorsia

J&J sends blood pressure drug back to Idorsia

J&J sends blood pressure drug back to Idorsia

BioPharma Dive

Flag link:

Sleepless nights for 500 Idorsia staff as biotech halves cash burn to outlast weak insomnia drug sales

Sleepless nights for 500 Idorsia staff as biotech halves cash burn to outlast weak insomnia drug sales

Fierce Biotech

Flag link:

Idorsia in Exclusive Talks for up to CHF 400 Million Strategic Deal for Asia Pacific (ex-China) Operations

Idorsia in Exclusive Talks for up to CHF 400 Million Strategic Deal for Asia Pacific (ex-China) Operations

Globe Newswire

Flag link:

Defense Department backs new study of Idorsia's Quviviq as a treatment for PTSD

Defense Department backs new study of Idorsia's Quviviq as a treatment for PTSD

Fierce Pharma

Department of Defense

Flag link:

Idorsia shares sink on ‘unexpected’ failure of drug study

Idorsia shares sink on ‘unexpected’ failure of drug study

BioPharma Dive

clinical trials

Flag link:

Neurocrine's $50M bet on Idorsia drug flames out in second PhII

Neurocrine's $50M bet on Idorsia drug flames out in second PhII

Endpoints

clinical trials

epileptic encephalopathy

Flag link:

J&J, Idorsia plan filings for aprocitentan data in resistant hypertension

J&J, Idorsia plan filings for aprocitentan data in resistant hypertension

Pharmaphorum

resistant hypertension

Flag link:

J&J's $230M blood pressure bet hits phase 3 endpoint, but questions linger about blockbuster potential

J&J's $230M blood pressure bet hits phase 3 endpoint, but questions linger about blockbuster potential

Fierce Biotech

clinical trials

Flag link:

Idorsia drug fails to quell binge eating in midphase trial, driving biotech to abandon the indication

Idorsia drug fails to quell binge eating in midphase trial, driving biotech to abandon the indication

Fierce Biotech

clinical trials

binge eating disorder

Flag link:

Idorsia's recently approved insomnia drug Quviviq hits the shelves

Idorsia's recently approved insomnia drug Quviviq hits the shelves

Bizjournals

Flag link:

Idorsia scores FDA go-ahead for insomnia drug Quviviq to rival Merck’s Belsomra, Eisai’s Dayvigo

Idorsia scores FDA go-ahead for insomnia drug Quviviq to rival Merck’s Belsomra, Eisai’s Dayvigo

Fierce Pharma

Flag link:

Idorsia hoping to make its dreams come true with a new insomnia alliance

Idorsia hoping to make its dreams come true with a new insomnia alliance

Fierce Pharma

pharma marketing

Flag link:

Idorsia sets itself up for failure

Idorsia sets itself up for failure

EP Vantage

clinical trials

Flag link:

Late-stage letdown for lucerastat dents Idorsia stock

Late-stage letdown for lucerastat dents Idorsia stock

Pharma Letter

clinical trials

Flag link:

Santhera bags DMD drug in 3-way deal with Idorsia and ReveraGen

Santhera bags DMD drug in 3-way deal with Idorsia and ReveraGen

Fierce Biotech

Duchenne Muscular Dystrophy

Flag link:

Second PhIII study for Idorsia's sleep drug returns positive results, but also raises new questions

Second PhIII study for Idorsia's sleep drug returns positive results, but also raises new questions

Endpoints

clinical trials

Flag link:

Idorsia's rival to Merck's insomnia drug clears phase 3 test

Idorsia's rival to Merck's insomnia drug clears phase 3 test

Fierce Biotech

clinical trials

Flag link:

Neurocrine signs $400M-plus deal with Idorsia for epilepsy drug

Neurocrine signs $400M-plus deal with Idorsia for epilepsy drug

Pharmaforum

Neurocrine Biosciences

pediatric epilepsy

Flag link:

Idorsia confirms 2019 spending plan as clinical trials "on track"

Idorsia confirms 2019 spending plan as clinical trials "on track"

Yahoo/Reuters

clinical trials

Flag link:

Pages